Xenon Pharmaceuticals Net Income
| XENE Stock | USD 41.48 0.14 0.34% |
As of the 15th of February 2026, Xenon Pharmaceuticals maintains the Downside Deviation of 1.99, market risk adjusted performance of 0.3231, and Mean Deviation of 1.63. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xenon Pharmaceuticals, as well as the relationship between them. Please check out Xenon Pharmaceuticals variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Xenon Pharmaceuticals is priced fairly, providing market reflects its latest price of 41.48 per share. Given that Xenon Pharmaceuticals has jensen alpha of 0.1029, we strongly advise you to confirm Xenon Pharmaceuticals's prevalent market performance to make sure the company can sustain itself at a future point.
Xenon Pharmaceuticals Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 366.8568 | Revenue | Earnings Share (3.89) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -210.9 M | -200.4 M | |
| Net Loss | -210.9 M | -200.4 M | |
| Net Loss | -112.4 M | -106.8 M | |
| Net Loss | (2.71) | (2.84) | |
| Net Income Per E B T | 1.13 | 1.10 |
Xenon | Net Income | Build AI portfolio with Xenon Stock |
Analyzing Xenon Pharmaceuticals's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Xenon Pharmaceuticals's current valuation and future prospects.
Latest Xenon Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Xenon Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Xenon Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Xenon Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Xenon Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xenon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (234.33 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Xenon Net Income Regression Statistics
| Arithmetic Mean | (71,167,303) | |
| Coefficient Of Variation | (118.99) | |
| Mean Deviation | 71,202,745 | |
| Median | (30,704,000) | |
| Standard Deviation | 84,678,632 | |
| Sample Variance | 7170.5T | |
| Range | 247.3M | |
| R-Value | (0.88) | |
| Mean Square Error | 1732.7T | |
| R-Squared | 0.77 | |
| Slope | (14,747,648) | |
| Total Sum of Squares | 114727.5T |
Xenon Net Income History
Other Fundumenentals of Xenon Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Xenon Pharmaceuticals Net Income component correlations
Xenon Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Xenon Pharmaceuticals is extremely important. It helps to project a fair market value of Xenon Stock properly, considering its historical fundamentals such as Net Income. Since Xenon Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Xenon Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Xenon Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Xenon diversify its offerings? Factors like these will boost the valuation of Xenon Pharmaceuticals. Anticipated expansion of Xenon directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xenon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.89) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Xenon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Xenon's accounting equity. The concept of intrinsic value - what Xenon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Xenon Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Xenon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Xenon Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Xenon Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Xenon Pharmaceuticals.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Xenon Pharmaceuticals on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Xenon Pharmaceuticals or generate 0.0% return on investment in Xenon Pharmaceuticals over 90 days. Xenon Pharmaceuticals is related to or competes with Centessa Pharmaceuticals, Apogee Therapeutics, Ascentage Pharma, Ultragenyx, Celcuity LLC, Zai Lab, and CG Oncology. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat pati... More
Xenon Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Xenon Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Xenon Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.99 | |||
| Information Ratio | 0.0329 | |||
| Maximum Drawdown | 10.56 | |||
| Value At Risk | (2.67) | |||
| Potential Upside | 3.78 |
Xenon Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xenon Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Xenon Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Xenon Pharmaceuticals historical prices to predict the future Xenon Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0601 | |||
| Jensen Alpha | 0.1029 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.0339 | |||
| Treynor Ratio | 0.3131 |
Xenon Pharmaceuticals February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0601 | |||
| Market Risk Adjusted Performance | 0.3231 | |||
| Mean Deviation | 1.63 | |||
| Semi Deviation | 1.83 | |||
| Downside Deviation | 1.99 | |||
| Coefficient Of Variation | 1492.26 | |||
| Standard Deviation | 2.05 | |||
| Variance | 4.19 | |||
| Information Ratio | 0.0329 | |||
| Jensen Alpha | 0.1029 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.0339 | |||
| Treynor Ratio | 0.3131 | |||
| Maximum Drawdown | 10.56 | |||
| Value At Risk | (2.67) | |||
| Potential Upside | 3.78 | |||
| Downside Variance | 3.94 | |||
| Semi Variance | 3.34 | |||
| Expected Short fall | (1.76) | |||
| Skewness | (0.02) | |||
| Kurtosis | 0.2705 |
Xenon Pharmaceuticals Backtested Returns
At this point, Xenon Pharmaceuticals is very steady. Xenon Pharmaceuticals shows Sharpe Ratio of 0.0268, which attests that the company had a 0.0268 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Xenon Pharmaceuticals, which you can use to evaluate the volatility of the company. Please check out Xenon Pharmaceuticals' Mean Deviation of 1.63, market risk adjusted performance of 0.3231, and Downside Deviation of 1.99 to validate if the risk estimate we provide is consistent with the expected return of 0.0546%. Xenon Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The firm maintains a market beta of 0.41, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Xenon Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Xenon Pharmaceuticals is expected to be smaller as well. Xenon Pharmaceuticals right now maintains a risk of 2.04%. Please check out Xenon Pharmaceuticals semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if Xenon Pharmaceuticals will be following its historical returns.
Auto-correlation | -0.17 |
Insignificant reverse predictability
Xenon Pharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Xenon Pharmaceuticals time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Xenon Pharmaceuticals price movement. The serial correlation of -0.17 indicates that over 17.0% of current Xenon Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.17 | |
| Spearman Rank Test | 0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 0.7 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Xenon Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Xenon Pharmaceuticals reported net income of (234.33 Million). This is 168.66% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 141.04% higher than that of the company.
Xenon Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xenon Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xenon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xenon Pharmaceuticals by comparing valuation metrics of similar companies.Xenon Pharmaceuticals is currently under evaluation in net income category among its peers.
Xenon Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Xenon Pharmaceuticals from analyzing Xenon Pharmaceuticals' financial statements. These drivers represent accounts that assess Xenon Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Xenon Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 531.3M | 1.4B | 2.4B | 3.1B | 2.7B | 2.9B | |
| Enterprise Value | 489.6M | 1.2B | 2.3B | 2.9B | 2.6B | 2.8B |
Xenon Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Xenon Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Xenon Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Xenon Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Xenon Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Xenon Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Xenon Pharmaceuticals' value.| Shares | Holocene Advisors, Lp | 2025-06-30 | 1.8 M | Alliancebernstein L.p. | 2025-06-30 | 1.5 M | Pictet Asset Manangement Sa | 2025-06-30 | 1.5 M | State Street Corp | 2025-06-30 | 1.4 M | Deep Track Capital, Lp | 2025-06-30 | 1.4 M | Adage Capital Partners Gp Llc | 2025-06-30 | 1.3 M | Jpmorgan Chase & Co | 2025-06-30 | 1.3 M | Westfield Capital Management Company, L.p. | 2025-06-30 | 1.2 M | Affinity Asset Advisors, Llc | 2025-06-30 | 1.1 M | Fmr Inc | 2025-06-30 | 8.9 M | Venbio Select Advisor Llc | 2025-06-30 | 5.4 M |
Xenon Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (45.44) % | ||||
| Current Valuation | 2.75 B | ||||
| Shares Outstanding | 77.28 M | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 99.90 % | ||||
| Number Of Shares Shorted | 5.54 M | ||||
| Price To Earning | (1.75) X | ||||
| Price To Book | 5.73 X | ||||
| Price To Sales | 427.38 X | ||||
| Gross Profit | (265.21 M) | ||||
| EBITDA | (235.86 M) | ||||
| Net Income | (234.33 M) | ||||
| Cash And Equivalents | 788.24 M | ||||
| Cash Per Share | 12.66 X | ||||
| Total Debt | 9.02 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 57.86 X | ||||
| Book Value Per Share | 7.25 X | ||||
| Cash Flow From Operations | (181.39 M) | ||||
| Short Ratio | 5.32 X | ||||
| Earnings Per Share | (3.89) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 55.82 | ||||
| Number Of Employees | 316 | ||||
| Beta | 0.93 | ||||
| Market Capitalization | 3.21 B | ||||
| Total Asset | 798.14 M | ||||
| Retained Earnings | (899.47 M) | ||||
| Working Capital | 599.67 M | ||||
| Current Asset | 60.87 M | ||||
| Current Liabilities | 2.78 M | ||||
| Net Asset | 798.14 M |
About Xenon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xenon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xenon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xenon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:Check out For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Will Biotechnology sector continue expanding? Could Xenon diversify its offerings? Factors like these will boost the valuation of Xenon Pharmaceuticals. Anticipated expansion of Xenon directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xenon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.89) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Xenon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Xenon's accounting equity. The concept of intrinsic value - what Xenon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Xenon Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Xenon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.